tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Argenx price target raised to $808 from $795 at Jefferies

Jefferies raised the firm’s price target on Argenx (ARGX) to $808 from $795 and keeps a Buy rating on the shares. The Vyvgart ADAPT SERON Phase 3 hit primary endpoint of day 29 myasthenia gravis activities of daily living change from baseline, the analyst tells investors in a research note. The firm increased its U.S. peak sales estimate for Vyvgart in myasthenia gravis to $3.8B.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1